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Abstract. A pharmacodynamic model introduced earlier in the literature for in silico pre-
diction of rifampicin-induced CYP3A4 enzyme production is described and some aspects
of the involved curve-fitting based parameter estimation are discussed. Validation with our
own laboratory data shows that the quality of the fit is particularly sensitive with respect to
an unknown parameter representing the concentration of the nuclear receptor PXR (preg-
nane X receptor). A detailed analysis of the influence of that parameter on the solution
of the model’s system of ordinary differential equations is given and it is pointed out that
some ingredients of the analysis might be useful for more general pharmacodynamic mod-
els. Numerical experiments are presented to illustrate the performance of related parameter
estimation procedures based on least-squares minimization.
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1. Introduction
Efficient modelling and simulation of drug distribution profiles in organs is be-
coming increasingly important. This is true not only for theoretical pharmacology,
where the main goal is often to describe the action of administered ligands (drugs)
on the cellular level, like its influence on receptors and metabolizing enzymes, but for
clinical pharmacy as well [19]. Drug concentration models help in designing patient-
tailored dosing regimens and represent an important tool for the assessment of drugs
safety before their approval by a state drug control institute. For instance, the US
Food and Drug Administration is frequently processing computer simulation based
analyses in regulatory submissions [20].
The advantages of in silico (numerical) experiments have for some time been
routinely exploited in pharmacology, just like in other fields of health and natural
sciences. Clearly, in vitro experiments are time consuming and demanding with
respect to financial and human resources. Acquisition and preparation of chemicals,
including cell cultivation, followed by drug administration and laboratory analysis
to produce measurement data, is a process that can easily take several months.
For in vivo trials the time, labor, and financial costs are even higher. In silico
computer simulations, on the other hand, gain attractiveness as they become more
reliable, affordable and user friendly [17]. Nowadays, dedicated software is available
(e.g. ADAPT [1], CellDesigner [4], Simcyp [18], NONMEM [15]).
In some situations, reliable in silico simulations can be indispensable. There is
a significant gap between the knowledge on rodent and on human drug distribution
behavior because human in vivo experiments are often infeasible (for safety reasons,
because of ethical objections, in clinical pediatrics, etc.). Often the only viable op-
tion to bridge this gap is through extrapolation of experimental data from rodents to
humans using an appropriate model. Another important issue in modern pharma-
cology are drug-drug interactions (DDI’s). DDI’s are in general poorly understood
and decisions are sometimes made based on a trial-and-error approach which, in
the worst case, can have fatal consequences. Mathematical models that quantify
drug-drug-interactions might offer useful guidance for practitioners when facing the
challenges of drug administration decisions in multi-drug therapy.
The primary goal of the so-called physiologically-based pharmacokinetic (PBPK)
and pharmacodynamic models is to provide time-profiles of the concentrations of the
involved substances (drugs, receptors, metabolizing enzymes) in several parts of the
body. This is done using compartmental models, where it is assumed that substance
concentrations are distributed homogeneously over the entire compartment [2]. Ex-
amples of compartments include plasma, intracellular and extracellular fluid, adipose
tissue, organs, cells, but they can represent abstract units as well [8]. The defined
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compartments depend for instance on the route of administration (intravenous, oral,
etc.), the target organs and the modelled ligand-induced processes. These processes
are described based on the assumed bio-physical laws and take the form of ordinary
differential equations (ODEs). As the involved substances usually react with several
of the other substances, the result is a system of in general nonlinear differential
equations whose size is at least equal to the total number of substances; substances
appearing in more than one compartment have to be split accordingly and increase
the size of the system. Nevertheless, the size is usually moderate (at most, say, 25)
and the system can be solved numerically in reasonable time (as long as the system
of ODEs is not too stiff).
A serious problem however is that not all the constants (parameters) in the system
of differential equations are readily available. The model’s parameters include diffu-
sion coefficients, elimination and production rates, organ volumes, systemic clearance
or blood flow rates. Some of these physiologic parameters are known from the litera-
ture or easily obtained from experimental measuring, but typically at least a small
number needs to be estimated. Parameter estimation is an integral part of the PBPK
and pharmacodynamic modelling process. Sometimes this is done through Monte-
Carlo Markov-Chain simulations, requiring a high number of solutions of the system
of ODEs [11]. Traditionally, parameter estimation is performed using the collected
experimental data from donors and the subsequent curve fitting, i.e. minimization of
a sum of squares based on comparing observed and model predicted concentrations.
The numerical minimization procedure is in general iterative. As a consequence, in
every iteration, the entire system of differential equations needs to be solved with
updated values for the parameters to be estimated. Efficient numerical optimization
has therefore a crucial influence on the overall computational time of the PBPK or
the pharmacodynamic modelling process.
The goal of this paper is to highlight some aspects of the numerical curve fitting
based parameter estimation involved in pharmacodynamic models. We will demon-
strate these with a model introduced by Luke et al. [9] for xenobiotics binding to the
pregnane X nuclear receptor (PXR) and inducing CYP3A4 enzymes. In the next
section, this model is described in detail and its ability to predict the concentrations
measured in our own laboratory experiments is discussed. In fact, the predictions
are not very accurate but we discovered through trial-and-error that they can be
considerably improved by doubling the value of one of the parameters as estimated
in Luke et al. [9]. In Section 3 we present an analysis to explain this fact theoretically.
Section 4 discusses relevance and possible consequences of the analysis for more gen-
eral cases and presents related numerical experiments. The last section points out
some future work and concludes the paper.
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2. A compartmental model for PXR-induced CYP3A4 production
We will consider a pharmacodynamic model introduced by Luke et al. [9] for
prediction of in vitro measurements of intracellular substance concentrations. The
model for the action of a xenobiotic (here the drug rifampicin) is schematically given
in Figure 1 (which also appeared in our publication [3]). We will briefly describe














Figure 1. Schematic representation of the modelled PXR-mediated processes. Numbered
squares represent the following reactions: (1) the xenobiotic enters the cell; (2)
PXR binds to the xenobiotic, leading to formation of PXR/RXRα heterodimer;
(3) PXR/RXRα dimer binds to DNA, increasing transcription; (4) mRNA back-
ground production; (5) degradation of mRNA; (6) the translation of mRNA forms
the protein; (7) degradation of the CYP3A4 protein; (8) the CYP3A4 protein me-
tabolizes the xenobiotic.
When the xenobiotic enters the cell,1 it initiates several processes. A PXR/RXR
(PR) heterodimer is created through binding to the nuclear receptor PXR. The het-
erodimer translocates to the nucleus where it stimulates, through processes described
later, the production of the CYP3A4 enzyme. The enzyme, however, metabolizes
not only the subtances that cause the disease, but the rifampicin as well. Besides
this feedback-loop of the xenobiotic, rifampicin is also returned after dissociation of
the heterodimer.
Similarly to [9], the changes of the xenobiotic concentration outside the cell
Xext(t)[µM] and inside the cell Xint(t)[µM] are represented by the following equa-
tions based on the assumption that the transport rate across the membrane is directly
proportional to the coefficient kup, to the difference in solution concentrations, and
1 It is assumed that rifampicin enters the cell across the membrane by a simple diffusion
process [21], i.e., the diffusion flux J is modelled in the compartmental framework as
follows: J = −kup(Xext(t)−Xint(t)). The variables and parameters are described in the
main text.
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= d(t) − kupXext(t) + kupXint(t),




= kupXext(t)− kupXint(t)− kassocXint(t)(sPXR − PR(t))
− kmetCYP3A4(t)Xint(t) + kdisPR(t).
Here, kup[1/min] is the first order diffusion coefficient encompassing the permeabil-
ity coefficient and the area of the membrane, kassoc[1/min], kmet[1/(µMmin)], and
kdis[1/min] are the corresponding association, metabolization, and dissociation con-
stants, respectively. An important parameter (as will be seen later) is the total
system PXR concentration (binded and free) sPXR[µM].




= kassocXint(t)(sPXR − PR(t)) − kdisPR(t),
where it is assumed that PR dissociates as well.
As the amount of rifampicin is increased, the increased concentration of the het-
erodimer causes it to enter the nucleus where it induces increased CYP3A4 mRNA




= kmRNAPR(t)− kmRNA,degmRNA(t) + pmRNA,back,
where kmRNA[1/min] is the transcription constant for mRNA. Moreover, back-
ground production and degradation of mRNA with the corresponding constants
pmRNA,back[µM/min] and kmRNA,deg[1/min] are assumed.
The result of mRNA translocation into the cytoplasm is the production of the





where kcyp[1/min] is a translation constant for CYP3A4. Also, degradation of
CYP3A4 with the corresponding constant kcyp,deg[1/min] is assumed.
Equations (2.1) through (2.5) define a system of ODEs of size five. The values of
mRNA and CYP3A4 are usually given as fold induction. It means that these values
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The initial concentrations of the remaining substances are assumed to be zero. How-
ever, in the simulations presented in [9] the dosing function d(t) is not used. Instead,











Table 1. The values of known parameters.
Most of the parameters in the ODEs can be taken from previously published
papers; their values are reported in Table 1. Note that the parameter kassoc is
computed based on the value of the unknown parameter kdis. The other unknown
parameters are sPXR, kmet and pmRNA,back. They have been estimated in [9] through
curve-fitting to experimental data. Their estimated values can be found for instance
in the first columns of Tables 5 and 6.
Experimental data needed for curve fitting computations often contain the concen-
trations of only some of the substances, like the xenobiotic concentration outside the
cell Xext(t) and the CYP3A4 mRNA concentration mRNA(t). In particular, PXR
concentrations appear to be difficult to measure.
We validated the model of Luke et al. with our own experimental data. In our
experiment, primary human hepatocytes were treated with 10µM of rifampicin. The
expression level profiles of mRNA for the CYP3A4 enzyme were analyzed using the
qRT-PCR method at 0, 6, 12, 24, 48, and 96 h from the beginning of the treatment.
The measured average fold levels are displayed as circles in Figures 2 and 3 with the
vertical lines displaying the corresponding standard deviation (every measurement
was repeated twice) and the solid lines giving the levels predicted by the model of
Luke et al., using our own Matlab [12] implementation. In Figure 2, we used the
literature parameter values in Table 1 and for the unknown parameters we used the
values as estimated by Luke et al. Clearly, our experimental data do not fit well with
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the predicted concentrations. However, one of the estimated parameters, sPXR, is
the total amount of PXR in the cell. To our surprise, we observed by simple manual
modification of this parameter, that doubling its value resulted in rather satisfactory
fitting as can be seen in Figure 3 (except for the time-point 48 hours, which seems to
be an outlier caused by inappropriate physical circumstances that might be ignored).
This observation has also been described in [3].

































Figure 2. Time profiles of CYP3A4 mRNA induction simulated employing the model by
Luke et al. [9] with an estimated total (free and bound) intracellular PXR con-
centration of 9.47·10−7 µM.

































Figure 3. Time profiles of CYP3A4 mRNA induction simulated employing the model by
Luke et al. [9] with an estimated total (free and bound) intracellular PXR con-
centration of 2 · 9.47·10−7 µM.
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3. Analysis
In this section we try to give an explanation for the fact that our laboratory data
can be fitted rather satisfactorily by simply doubling the value for the parameter
sPXR as estimated in [9]. We give a straightforward analysis, which for this special
situation appears to give some insight.
First we introduce new notation. The unknown substance concentrations will be










































We will also change the notation of all constants except sPXR (which is the parameter
of main interest) and define:
k1 ≡ kup, k2 ≡ kassoc, k3 ≡ kmet, k4 ≡ kdis, k5 ≡ kmRNA,
k6 ≡ kmRNA,deg, k7 ≡ pmRNA,back, k8 ≡ kcyp, k9 ≡ kcyp,deg.
I5 will denote the identity matrix of size five, ei its ith column. Then the system of




= Bx(t) + z(t),









−k1 k1 0 0 0
k1 −(k1 + k2sPXR) k4 0 0
0 k2sPXR −k4 0 0
0 0 k5 −k6 0


















k2 · x2(t) · x3(t)− k3 · x2(t) · x5(t)











representing the nonlinear (quadratic) and constant parts. The initial conditions





















in our situation, x1(0) is the initially applied dose, i.e. x1(0) = 10µM, and x4(0) =
7.075·10−6 µM and x5(0) = 0.0655µM are the steady (initial) state concentrations
for mRNA and CYP3A4, respectively.
In our analysis we will use the linearized version of the system of differential





= ∇f(x(0)) · x(t) + b, b ≡ ( 0 0 0 k7 0 )
T
,
where due to the given initial conditions x2(0) = x3(0) = 0 we have
(3.5)








−k1 k1 0 0 0
k1 −(k1 + k2sPXR)− k3x5(0) k4 0 0
0 k2sPXR −k4 0 0
0 0 k5 −k6 0









Solutions of this linearized problem are given explicitly as
(3.6) xl(t) = e
Ct(x(0) + y)− y, where Cy = b.








−k1 k1 0 0 0
k1 −(k1 + k2sPXR)− k3x5(0) k4 0 0
0 k2sPXR −k4 0 0
0 0 k5 −k6 0
















































































In Figures 4 and 5 we see that this solution gives satisfactory approximations of
the numerical solution of the true differential equations system (3.1) for the range
of interest for sPXR and for the times corresponding to the first few experimental
data, i.e. after 6, 12 and 24 hours. We will next concentrate on the analysis of the
linearized system of differential equations (3.4) with (3.5) to explain the influence of
the parameter sPXR on its solution in the hope of explaining, at least for the times
t = 6 · 60, t = 12 · 60 and t = 24 · 60 minutes, why doubling the value estimated
in [9] for sPXR gives a remarkably good fit when using the true differential equations
system (3.1).


































Figure 4. Time profiles of CYP3A4 mRNA induction modelled by numerical solution of
(3.1) and by the solution of the linearized system (3.4) with an estimated total
(free and bound) intracellular PXR concentration of 9.47·10−7 µM.
We will use the fact that any matrix function can be expressed as a polynomial
in that matrix, where the degree of the polynomial is at most the size of the matrix
minus one. Hence, for the matrix exponential eCt in (3.6) we have







































Figure 5. Time profiles of CYP3A4 mRNA induction modelled by numerical solution of
(3.1) and by the solution of the linearized system (3.4) with an estimated total
(free and bound) intracellular PXR concentration of 2 · 9.47·10−7 µM.
see e.g. [13]. The coefficients p0, . . . , p4 of the polynomial can be computed using
for instance Sylvester’s formula. They depend on t as well as on the matrix entries,
including the parameter sPXR we are interested in. However, the influence of sPXR
on these coefficients is very limited. In Table 2 we display these coefficients for eC1 ,
where in C1 the parameter sPXR has the value sPXR = 9.47·10
−7 µM estimated in
Luke [9], and for eC10 , where in C10 the parameter sPXR has the value sPXR =
9.47·10−6 µM ten times the estimate in Luke [9]. We also display the coefficients for
eC1·6000 and eC10·6000, which corresponds to the time t = 6000 several hours after the
last laboratory observation. We see that only the last digits of the coefficients are
affected if we increase the estimate for sPXR with a factor 10 (when increasing with
a factor two, no differences are visible in most coefficients).
eC1 eC10 eC1·6000 eC10·6000
p0 1.000000000000000 1.000000000000000 1.001057025103826 1.001057024996506
p1 1.000000000000121 1.000000000000121 1.219084306280218 1.219084449821729
p2 0.500000000731660 0.500000000731659 0.770726157661988 0.770726071609689
p3 0.166662411269497 0.166662411269437 0.012736370268294 0.012736368725253
p4 0.041228702593904 0.041228702592610 0.000039775431340 0.000039775426415
Table 2. Coefficients pi in (3.8) for the original estimate of sPXR (first and third column)
and tenfold of the original estimate (second and fourth column), for times t = 1
(first two columns) and t = 6000 (last two columns).
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In the following we will therefore neglect the influence of sPXR on the pi and
restrict ourselves to the analysis of the influence of sPXR on the powers of C in (3.8).
For the influence of any paramater appearing in the matrix C in (3.5) we have the
following result.
Theorem 3.1. Neglecting the influence of parameters on the coefficients pi
in (3.8), for any time t, the solution (3.6) of the linearized system (3.4) with (3.5)
depends on any parameter ki appearing in (3.5), including sPXR, according to a ra-
tional function n(k)/d(k), where the numerator n(k) is a polynomial of degree at
most 5 and the denominator d(k) is a polynomial of degree at most 1.
P r o o f. Using (3.8), the term eCtx(0) in (3.6) equals




Clearly, every component of eCtx(0) is a polynomial in ki of degree at most four. As
for the second term y in (3.6), a look at the solution (3.7) shows that the constants
k6 and k9 appear in the denominator. Hence, for these parameters we have a rational
function in that parameter where the denominator is a linear function. Combination
with the term eCtx(0) gives the claim. 
For some parameters, the influence addressed in the above theorem is described
by a function simpler than a rational function. For instance, for the parameter sPXR









−k1 k1 0 0 0
k1 −k1 − k3x5(0) k4 0 0
0 0 −k4 0 0
0 0 k5 −k6 0







































−k1 k1 0 0 0
k1 −k1 − k3x5(0) k4 0 0
0 0 −k4 0 0
0 0 k5 −k6 0





























then the term eCtx(0) in (3.6) can be written as




= p0x(0) + p1t(C2 − βe23e
T















where we used (3.8). However, because of the special form of the initial condi-
tions (3.3), the inner product eT2 x(0) appearing often in (3.10) is zero. Therefore, in























The same can be done for all other powers of C2 − βe23e
T
2 . It is easy to see that in
every case about half of the terms vanish.
In addition, for our analysis we are only interested in fitting to the experimental
data measured for CYP3A4 mRNA induction, i.e. in the fourth component of the















Doing this for all other powers of C2 − βe23e
T
2 as well, we obtain the following
simplification.
Proposition 3.1. Neglecting the influence of β on the coefficients pi in (3.8),
the fourth component of the vector eCtx(0) in (3.6) depends on β quadratically as
follows:
eT4 e






4 x(0) + p1t(e
T


































ix(0) for i = 0, . . . , 4 and exploiting the fact that eT2 x(0) = 0 and e
T
4 e23 = 0.

Analogous simplifications can be carried out for the influence of some other pa-
rameters, like, for example, k4.
The second term y in (3.6) does not depend on β at all, see (3.7). Summarizing,
for the fourth component of the solution of the linearized model, which approximates
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the true model simulation for CYP3A4 mRNA induction, we obtain the following
corollary.
Corollary 3.1. Neglecting the influence of β on the coefficients pi in (3.8), the
fourth component of the solution eT4 xl(t) of the linearized system (3.4) with (3.5)
depends quadratically on β as follows:



















− y4 + p0e
T
4 x(0) + p1t(e
T











P r o o f. The claim follows from eT4 xl(t) = e
T
4 e
Ctx(0) − eT4 y and from Proposi-
tion 3.1. 
In the first two rows of Table 3 the observed, laboratory CYP3A4 mRNA average
fold induction values for the times t1 = 6·60, t2 = 12·60, t3 = 24·60, t4 = 48·60
and t5 = 96·60 minutes are displayed with their standard deviations. Let us denote
them by O(ti) for the given time points. As mentioned, fold induction values are
relative values with respect to steady state. In the model of Luke et al. they are
predicted by the values mRNA(ti)/mRNASS , with the steady-state concentration
mRNASS = 7.075·10
−6 µM. For particular estimates of the parameter sPXR and
for the given time points, these predictions are displayed in the remaining rows of
Table 3.
time (min) t1 = 360 t2 = 720 t3 = 1440 t4 = 2880 t5 = 5760
O(t) 7.36 19.23 30.01 75.57 83.88
stand. dev. for O(t) ±1.51 ±2.84 ±7.72 ±19.86 ±2.09
sPXR = 9.47·10
−7 4.06 8.04 15.24 26.87 41.87
sPXR = 2·9.47·10
−7 7.12 15.08 29.46 52.63 81.79
sPXR: solution of (3.11) 7.285 18.724 28.322 66.895 66.027
sPXR: solution of (3.12) 7.069 14.974 29.239 52.231 81.172
Table 3. CYP3A4 mRNA induction: Observed values (first row), their standard devia-
tions (second row) and values predicted (remaining rows) with the model (3.1) for
several choices of the parameter sPXR.






where xl(t) is given in (3.6). If we wish to find the parameter β for which our
linearized model fits the observed data best at a given time point, we can solve the
quadratric equation
(3.11) q2(ti)β
2 + q1(ti)β + q0(ti) = mRNASSO(ti),
with coefficients
q0(t) = y4 + p0e
T
4 x(0) + p1t(e
T






























see Corollary 3.1. We note that the coefficients pi depend on t; we have omitted this
dependence for simplicity of presentation.
Table 4 shows the solutions of the quadratic equation in (3.11) for the time points
used in the in vitro experiment. It displays the corresponding values for sPXR as well.
We see that these values are close (in particular for the time points 6 and 24 hours)
to the double value sPXR = 2·9.47·10
−7 = 1.894·10−6 of the estimate obtained in [9],
which gave a surprisingly good fit, see Figure 3. The predictions that the individual
solutions of (3.11) give with the original, nonlinearized model (3.1) are displayed in
the last but one row of Table 3. They yield lower predictions than the linearized
model, which is what one would expect seeing the curves in Figures 2 and 3. For most
time points they fall inside the corresponding observation plus or minus the standard
deviation. But as only a single value for sPXR can be used for all time-points, the
quality of these predictions is of limited importance.
time (min) t1 = 360 t2 = 720 t3 = 1440 t4 = 2880 t5 = 5760
β 3.58·10−11 4.38·10−11 3.34·10−11 4.45·10−11 2.79·10−11
sPXR 1.95·10
−6 2.38·10−6 1.82·10−6 2.42·10−6 1.52·10−6
Table 4. Optimal values of β and sPXR from the solution of (3.11) for individual time
points.
If we wish to find an appropriate value of β (and hence sPXR) over all observed
times, we can solve the minimization problem
(3.12) min
β




















2 + q1(t1)β + q0(t1)−mRNASSO(t1)
q2(t2)β
2 + q1(t2)β + q0(t2)−mRNASSO(t2)
q2(t3)β
2 + q1(t3)β + q0(t3)−mRNASSO(t3)
q2(t4)β
2 + q1(t4)β + q0(t4)−mRNASSO(t4)
q2(t5)β





















We can solve this equation in a least-squares manner. The solution then is β =
3.456·10−11, hence sPXR = β/k2 = 1.879·10
−6. This is even closer to the double
value sPXR = 2·9.47·10
−7 = 1.894·10−6 of the estimate obtained in [9] than any of
the individual solutions of (3.11) and thus offers an explanation for the fact that
the double value sPXR = 2·9.47·10
−7 gives rather accurate predictions. The last row
of Table 3 displays the predictions obtained with the original, nonlinearized model
(3.1), where sPXR = 1.879·10
−6. They are of course very close to the predictions
with the double value sPXR = 2·9.47·10
−7 = 1.894·10−6. In fact they are slightly
smaller, which can be explained by the fact that we found an appropriate value for
the linearized model, which tends to give higher predictions than the original model.
4. Discussion and complementing numerical experiments
The analysis of the previous section is clearly tailored to a specific situation for an-
swering a particular question, which concerns merely one parameter to be estimated.
Nevertheless, some more general observations for curve-fitting based parameter es-
timation in pharmacodynamic models can be derived from it. Below we list some of
them.
⊲ Assuming a linearized version of the given pharmacodynamic model (i.e. an ODE
of the form (3.4)) yields good approximations of the predictions of the model itself,
we can analyze a system of linear ODEs where the system matrix C = ∇f(x(0))
is usually small, because only a limited number of substances is typically involved
(at most, say, 20–25).
⊲ The entries of C often depend linearly on the parameters of the model. This is true,
because many pharmacologic processes are described as zero or first-order reac-
tions, such as simple diffusion, membrane transport or degradation. An exception
is given by processes modelled using Michaelis-Menten kinetics (or a generaliza-
tion, the Hill-Langmuir equation), where a parameter appears in the denominator.
⊲ With a small matrix size and linear dependence on parameters, the entries of the
term eCtx(0) in the solutions (3.6) of the linearized model will approximately be
polynomials of low degree in the parameters. This follows from the fact that any
size n matrix function is a polynomial in that matrix of degree at most n − 1
(a consequence of the Cayley-Hamilton theorem). However, here we assume that
the dependence of the coefficients of the polynomial on the parameters is negligible.
The entries of the term y of (3.6), however, can be rational functions of some
parameters.
⊲ In typical situations, only a few of the parameters need to be estimated. Moreover,
these will be very sparsely spread over the matrix as they are involved in one of
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the modelled pharmacologic (or biophysical) processes only. They can appear
on several rows if several substances are involved, but in general, the unknown
parameters can be isolated in a small rank-modification of the matrix, as was
done in (3.9).
⊲ Several of the initial substance concentrations will be zero, i.e. several components
of x(0) are zero. In combination with the isolation from C of unknown parameters
in a small-rank matrix, the vector eCtx(0) may depend on unknown parameters
according to a polynomial of degree significantly lower than n− 1 (neglecting the
influence of that parameter on the polynomial representing eCt).
⊲ Data fitting is done with respect to the observed concentrations for some sub-
stances only (other substances may be very difficult to measure in vitro). A further
reduction of the degree of polynomial dependence holds for unknown parameters
appearing in the rows of C not corresponding to the row of the substance used
for data fitting. In favorable cases, a near-optimal estimate for some parameters
with respect to the linearized model can thus be found analytically. This may give
useful initial guesses for the original pharmacodynamic model.
⊲ The assumption that a linearized version of the pharmacodynamic model yields
good approximations of the predictions of the model itself can be too strong or
may hold only for the initial say 24 hours of the experiment. We remark, however,
that the numerical solution of the model, yielding its predictions, is sometimes
constructed through subsequent linearization after each time point.
⊲ The parameter estimation problem considered here is an idealized problem in the
sense that additional physical restrictions should be incorporated. Most parame-
ters are not allowed to be negative and are physically meaningful in a particular
interval only. The corresponding optimization problem represents therefore in
fact constraint optimization. Also, fitting to average observed concentrations (the
circles in Figures 2 and 3) does not take into account the natural deviation in
repeated laboratory experiments (measurement error); fitting requirements could
be relaxed. Finally, we modelled here with the actual physical parameter val-
ues; scaling them to avoid differences of many orders of magnitude between some
parameters might be appropriate.
In the remainder of this section we perform some complementary experiments
to further assess the dependence of the predicted CYP3A4 mRNA fold induction
x4(t) on the parameters sPXR, k1, . . . , k9. In contrast with the previous section we
focus on iterative numerical optimization of all unknown parameters simultaneously.
Instead of computations in Matlab [12], in this section most computations were
done in Fortran [5], but some, for comparison, were done in ADAPT [1], which is
an example of pharmakokinetic/dynamic systems software popular among clinical
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pharmacists. We recall that the experimental data are reported in the first row of
Table 3. The value at the time t4 = 48·60 = 2880 is somewhat outlying and might be
ignored. This is another typical aspect of parameter estimation in pharmacodynamic
modelling. In some cases the use of robust statistics for outlier detection may be
very beneficial.
First, we describe our Fortran experiments. An overview of the known parameters
involved in our model was given in Table 1. The parameters to be estimated are sPXR,
k3, k4, k7. For this purpose we introduce the vector k = (sPXR, k3, k4, k7)
T ∈ R4 and







where x(t) is the solution of (3.1); note that due to the dependence of x4(t) on the
parameters k we use the notation x4(t, k). For solving the involved system of ODEs
we used the ODEPACK solver [7], written in Fortran, with the option MF = 21.
In this case, an implicit backward differentiation formula method and a modified
Newton iteration with user-supplied analytical Jacobian are used, see [7] for more
details. We remark that the choice of parameters influences the stiffness of the ODE
as they are the ratio of smallest to largest eigenvalue real part of the matrix of the
linearized problem.
We will compare the quality of several parameter estimate choices using the
achieved value of the OLS function J . One choice are the values obtained in [9]
(based on minimization of an OLS function with different observed data), this is
approx # 1 in Table 5. Another choice, discussed in detail in the previous section,
differs in that we double the value of the parameter sPXR (approx # 2 in Table 5).
Next, we minimize the function J over all parameters in k with an optimization




Finally, as the value O4(t4) looks as an outlier, we performed minimization of J
without this point, i.e., the fourth summand in (4.1) is considered zero (approx # 4
in Table 5).
For minimization of the function J , the UFO optimization software library [10],
written in Fortran, was used. Starting from an initial guess k(0), a sequence of
iterations k(l+1) = k(l) + α(l)d(l) is constructed. Here, d(l) is a direction vector
determined on the basis of the values d(λ), J(k(λ)), ∇J(k(λ)) for λ = 1, . . . , l − 1,
and α(l) is a steplength (automatically) determined on the basis of the behavior of J
in a neighborhood of the point k(l). Note that the gradients ∇J(k(λ)) are computed
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numerically using finite differences. In all cases, we used Luke’s parameter values as
the starting point k(0) (displayed in the first column of Table 5).
In addition to numerical experiments where, as in [9], no dosing function is used,
i.e. d(t) = 0 with the initial value x1(0) = 10µM, we also performed numerical ex-
periments, where the dosing of 10µM during the first hour is translated by putting
d(t) = 1/6µM/min if t < 60 and initial value x1(0) = 0. The results of this second
type of computations are displayed in Table 6 (with approx # 5, 6, 7 and 8 corre-
sponding, respectively, to approx # 1, 2, 3 and 4 in Table 5). We note that having
x1(0) = 0 can further simplify the analysis like the one given in the previous section.
Tables 5–6 summarize the final parameters used to generate the approximation of
the CYP3A4 mRNA fold induction, i.e. the function x4(t, k) together with the value
of the OLS function J .
approx # 1 2 3 4
parameters Luke [9] double sPXR [3] (4.1) minimal without outlier
sPXR 9.47·10
−7 18.94·10−7 9.22·10−7 9.31·10−7
k3 2.47·10
−5 2.47·10−5 2.47·10−5 2.47·10−5
k4 1.03·10
−4 1.03·10−4 1.03·10−4 1.03·10−4
k7 2.83·10
−7 2.83·10−7 1.22·10−7 1.36·10−7
J(k) 4491.11 547.96 366.78 15.29
Table 5. Parameter values for d(t) = 0 and x1(0) = 10µM.
approx # 5 6 7 8
parameters Luke [9] double sPXR [3] (4.1) minimal without outlier
sPXR 9.47·10
−7 18.94·10−7 9.36·10−7 9.31·10−7
k3 2.47·10
−5 2.47·10−5 2.47·10−5 2.47·10−5
k4 1.03·10
−4 1.03·10−4 1.03·10−4 1.03·10−4
k7 2.83·10
−7 2.83·10−7 1.25·10−7 1.36·10−7
J(k) 4539.04 575.59 378.80 21.20
Table 6. Parameter values for d(t) = 1/6 and x1(0) = 0µM.
From the last row of both tables we can see that doubling the parameter sPXR
significantly improves the results. Not surprisingly, however, the best results (the
smallest value of the function J) are obtained using minimization of J and optimizing
all parameters sPXR, k3, k4, k7 at the same time. The very low values of J(k) in
the last columns are explained by the fact that the contribution of the time point
t4 = 48·60, which as an apparent outlier is the largest, is missing in the sum of
squares (4.1). Figures 6–7 show the corresponding curves of x4(t, k). Whereas the
curves for approx # 3 and 7 show the best global fit, the best fit with the apparent
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outlier omitted is for the curves for approx # 4 and 8. Nevertheless, the curves
for approx # 2 and 6 come remarkably close. Hence doubling the parameter sPXR
seems to give an estimate that is robust with respect to outliers. One might even be
tempted to think this suggests that the doubled parameter value sPXR = 18.94·10
−7
is close to the actual physically valid value. But such a claim is hard to make: The
interdonor variability of total PXR concentration (i.e. of sPXR) may be large; after
all, the originally estimated value sPXR = 9.47·10
−7 yielded a satisfactory fit for
other observed data, namely those that were used for curve-fitting in [9].


































Figure 6. CYP3A4 mRNA fold induction x4(t, k) for d(t) = 0 and x1(0) = 10µM.


































Figure 7. CYP3A4 mRNA fold induction x4(t, k) for d(t) = 1/6 and x1(0) = 0µM.
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From the results in Tables 5–6 we can deduce several other conclusions. First, it
seems that only the parameters sPXR and k7 influence the results qualitatively (the
parameters k3 and k4 are nearly identical over all columns). Concerning the situation
when there is no dosing, d(t) = 0, and initial x1(0) = 10µM and the situation when
there is administration of 10µM during the first hour (i.e. d(t) = 1/6µM/min) and
initial x1(0) = 0, one can see no significant difference in the optimal parameters and
curves. However, we report that the number of function evaluations (i.e. of ODE
runs) performed during the numerical iterative optimization processes were 168 and
148 for approximations # 3 and 4, respectively, whereas these were 2174 and 2202 for
approximations # 7 and 8, respectively. This can be explained by the discontinuity
of d(t) for approximations # 7 and 8: At the moment when t equals 60 minutes it
jumps from 1/6 to 0.
It may seem contradictory that the curves for approximations #2 and #4 (and
for # 6 and # 8) are very close while the corresponding parameters sPXR and k7
are rather different. To understand this phenomenon, we performed two additional
numerical tests consisting in producing curves with the value for sPXR fixed while
changing the value of k7 and vice versa. The results are depicted in Figures 8–9.
One can deduce that for fixed sPXR, the CYP3A4 mRNA fold induction curve is
higher with increasing k7, while for fixed k7, this curve is higher with decreasing
sPXR. Therefore, a curve with twice a greater value of sPXR can be close to one with
twice a smaller value of k7.
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Figure 8. CYP3A4 mRNA fold induction for sPXR = 9.47·10
−7.
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Figure 9. CYP3A4 mRNA fold induction for k7 = 2.83·10
−7.
Finally, we also present the parameters obtained when estimating with the stan-
dard pharmacokinetic/dynamic system software ADAPT frequently used by clinical
pharmacists. In ADAPT, ODE’s are solved by LSODA [16], [6], which uses variable
order and variable step size formulations of Adam’s method and Gear’s method for
respectively nonstiff and stiff equations. Function optimization for parameter estima-
tion is done using the Nelder-Mead simplex method [14] in order to take into account
the positivity constraint of the estimated pharmacokinetic/dynamic parameters. In
Tables 7–8 we display some results for the simulation without or with the dosing func-
tion d(t), respectively. The first two parameter columns give the estimated values
obtained from minimization of the OLS function J , with the second column ignoring
the apparent outlier at t4 = 48·60 = 2880 minutes. The achieved sums of squares
are smaller than in the corresponding last two columns in Tables 5–6 for three out
of four cases. We assume this is mainly caused by the fact that the simplex method
handles better the positivity constraints for the parameters than when UFO [10] was
used; in Fortran we imposed them in a naive, rather brute force way. The estimated
parameter values are rather different from those generated in Tables 5–6, indicating
that a different local minimum seems to have been found (though the initial guesses
were always the same, except that ADAPT rounds them to the sixth digit after the
comma). We remark that without the dosing function and when ignoring the outlier,
ADAPT estimates the parameter sPXR at roughly twice the original estimate from
Luke [9] as well.
274
parameters (4.1) minimal without outlier ML ML without outlier
sPXR 1.26·10
−5 1.81·10−6 1.61·10−6 1.8·10−6
k3 1.95·10
−5 1.08·10−4 1.82·10−4 1.09·10−4
k4 2.51·10
−10 7.65·10−7 5.34·10−8 7.54·10−7
k7 6.69·10
−4 5.14·10−7 2.9·10−5 1.58·10−7
J(k) 116.98 9.28 216.68 9.28
Table 7. Parameter values for d(t) = 0 and x1(0) = 10µM computed by ADAPT (ML:
Maximum likelihood estimator).
parameters (4.1) minimal without outlier ML ML without outlier
sPXR 5.78·10
−7 5.36·10−7 5.58·10−7 5.36·10−7
k3 5.74·10
−7 4.23·10−7 5.27·10−7 4.23·10−7
k4 1.27·10
−6 2.73·10−6 2.22·10−6 2.73·10−6
k7 1.2·10
−6 2.46·10−6 3.1·10−5 1.63·10−6
J(k) 73.86 30.65 56.05 30.66
Table 8. Parameter values for d(t) = 1/6 and x1(0) = 0µM computed by ADAPT (ML:
Maximum likelihood estimator).
The last two columns in Tables 7–8 display the results when instead of a standard
sum of squares minimization, a maximum likelihood (ML) approach is used. As
expected, this does not in general give lower values for the OLS function; nevertheless,
in the infusion with outlier case, ML does lead to a lower sum of squares. When
ignoring the outlier, ML seems to find the same local minimum as the classical least-
squares minimization. In the ML case, ADAPT estimates in addition the dependence
of the measurement error on time through a linear function for this dependence.
More precisely, it estimates, from user-defined initial guesses, the variances for the
probability distribution of the intercept and the slope.
5. Conclusion
Most pharmacodynamic models require estimation of at least a small number of
parameters. For the model of Luke et al. [9] that we investigated, we focussed on one
of the four unknown parameters, the overall concentration of the nuclear receptor,
because a modification of its estimate leads to a rather good fit of our own laboratory
observations. While the standard sensitivity analysis presented in [9] did not predict
a particularly outspoken influence of overall receptor concentration on the predicted
values used for curve-fitting, we presented a different analysis showing that this
influence can be approximately described by a quadratic polynomial. The proposed
type of analysis might be useful for other pharmacodynamic models as well. Though
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the final goal for future work, to give direct links between (1) the particular types and
parameters of modelled pharmacokinetic processes and (2) properties of the Hessian
matrices involved in the corresponding least-squares minimization, is out of reach for
the moment, we made a first step that might contribute to its realization.
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